Description: This is an article providing a summary of the SOA Research Institute's participation in an NAIC meeting that took place in December 2022. This article will also be disseminated via the SOA News Weekly, linking to the article posted on soa.org.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: LEARN is an offering to regulators about reinsurance. This article summarizes a session held for Brazilian health regulators in the fall of 2022.

Description: SMI Trust Fund: Estimates under Alternative II Assumption for Aged and Disabled Excluding End-Stage Renal Disease Enrollees from Pension Section News, October 2000, Issue No. 44.

Description: Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event. Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event.

Description: The article describes the sessions that the SIPF section sponsored - Paid Family Leave and Medicare and Medicaid Update. The Paid Family Leave session described what it is and what states it is currently in and how it is being implemented. The Medicare and Medicaid update gave the attendees the most up to date news about what is going on at the Federal level.

Description: This research report examines the potential implications of the risk mitigation programs – risk adjustment, reinsurance, and risk corridors – established under The Patient Protection and Affordable Care Act.

Description: This discussion at the SOA 2000 Las Vegas Spring Meeting focuses on the polictical landscape with respect to health care issues including Medicare, prescription drug coverage, the concept of a patient's 'bill of rights', and other health care reform ideas.

Description: Panelists discuss the future of prospective payment in Medicare, sequels to the Omnibus Budget Reconciliation Act, the Deficit Reduction Act, COBRA, fallout from the administration's Catastrophic Illness Study, and the evolution of the voucher proposal. From the 1987 Record of Society of Actuaries, Vol. 13, No. 1.

Description: Corin Chapman explores the many perspectives to consider when determining appropriate insurance regulation.